CXCL12/CXCR4 pathway is activated by oncogenic JAK2 in a PI3K-dependent manner.

PubWeight™: 0.75‹?›

🔗 View Article (PMID 28903325)

Published in Oncotarget on July 22, 2016

Authors

Hadjer Abdelouahab1,2,3,4, Yanyan Zhang1,3,4, Monika Wittner1,3,4, Shinya Oishi5, Nobutaka Fujii5, Rodolphe Besancenot1,3,4, Isabelle Plo1,3,4,6,7, Vincent Ribrag1,3,4, Eric Solary1,3,4, William Vainchenker1,3,4,7, Giovanni Barosi8, Fawzia Louache1,2,3,4

Author Affiliations

1: INSERM, UMR 1170, Gustave Roussy, Villejuif, France.
2: University Paris Diderot, Paris, France.
3: University Paris-Sud 11, Villejuif, France.
4: Gustave Roussy, Villejuif, France.
5: Kyoto University, Graduate School of Pharmaceutical Sciences, Kyoto, Japan.
6: Equipe labellisée Ligue Nationale contre le Cancer, UMR 1170, Institut Gustave Roussy, Villejuif, France.
7: Grex, Laboratoire d'Excellence, Paris, France.
8: Center for the Study of Myelofibrosis, Biotechnology Research Area, IRCCS Policlinico S. Matteo Foundation, Pavia, Italy.

Articles cited by this

Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet (2005) 18.59

A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature (2005) 18.43

Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell (2005) 17.41

Somatic mutations of calreticulin in myeloproliferative neoplasms. N Engl J Med (2013) 9.65

Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2. N Engl J Med (2013) 8.89

CXCL12 (SDF-1)/CXCR4 pathway in cancer. Clin Cancer Res (2010) 5.42

Haematopoietic stem cells and early lymphoid progenitors occupy distinct bone marrow niches. Nature (2013) 4.11

CXCL12 in early mesenchymal progenitors is required for haematopoietic stem-cell maintenance. Nature (2013) 4.04

JAK2V617F expression in murine hematopoietic cells leads to MPD mimicking human PV with secondary myelofibrosis. Blood (2006) 3.37

Rapid mobilization of functional donor hematopoietic cells without G-CSF using AMD3100, an antagonist of the CXCR4/SDF-1 interaction. Blood (2008) 3.11

The leukemic stem cell niche: current concepts and therapeutic opportunities. Blood (2009) 2.85

Characteristics and clinical correlates of MPL 515W>L/K mutation in essential thrombocythemia. Blood (2008) 2.09

High expression of the chemokine receptor CXCR4 predicts extramedullary organ infiltration in childhood acute lymphoblastic leukaemia. Br J Haematol (2001) 2.06

Relation between JAK2 (V617F) mutation status, granulocyte activation, and constitutive mobilization of CD34+ cells into peripheral blood in myeloproliferative disorders. Blood (2005) 2.00

Mechanism of human stem cell migration and repopulation of NOD/SCID and B2mnull NOD/SCID mice. The role of SDF-1/CXCR4 interactions. Ann N Y Acad Sci (2001) 1.79

Molecular pathways: Jak/STAT pathway: mutations, inhibitors, and resistance. Clin Cancer Res (2013) 1.59

Isoform-selective phosphoinositide 3'-kinase inhibitors inhibit CXCR4 signaling and overcome stromal cell-mediated drug resistance in chronic lymphocytic leukemia: a novel therapeutic approach. Blood (2009) 1.58

Reduced retention of radioprotective hematopoietic cells within the bone marrow microenvironment in CXCR4-/- chimeric mice. Blood (2005) 1.51

Diagnostic and clinical relevance of the number of circulating CD34(+) cells in myelofibrosis with myeloid metaplasia. Blood (2001) 1.45

Constitutive mobilization of CD34+ cells into the peripheral blood in idiopathic myelofibrosis may be due to the action of a number of proteases. Blood (2005) 1.35

Hypermethylation of CXCR4 promoter in CD34+ cells from patients with primary myelofibrosis. Stem Cells (2008) 1.30

Janus kinase 2 is involved in stromal cell-derived factor-1alpha-induced tyrosine phosphorylation of focal adhesion proteins and migration of hematopoietic progenitor cells. Blood (2001) 1.30

Aberrant signal transduction pathways in myeloproliferative neoplasms. Leukemia (2008) 1.25

Stromal-derived factor 1 and thrombopoietin regulate distinct aspects of human megakaryopoiesis. Blood (2000) 1.22

Neutrophil mobilization via plerixafor-mediated CXCR4 inhibition arises from lung demargination and blockade of neutrophil homing to the bone marrow. J Exp Med (2013) 1.21

Critical role for ERK1/2 in bone marrow and fetal liver-derived primary megakaryocyte differentiation, motility, and proplatelet formation. Exp Hematol (2009) 1.16

JAK2V617F allele burden and thrombosis: a direct comparison in essential thrombocythemia and polycythemia vera. Exp Hematol (2009) 1.16

A critical role of Rap1b in B-cell trafficking and marginal zone B-cell development. Blood (2008) 1.12

The expression of CXCR4 is down-regulated on the CD34+ cells of patients with myelofibrosis with myeloid metaplasia. Blood Cells Mol Dis (2007) 1.12

Spleens of myelofibrosis patients contain malignant hematopoietic stem cells. J Clin Invest (2012) 1.09

The effect of CXCL12 processing on CD34+ cell migration in myeloproliferative neoplasms. Cancer Res (2010) 1.03

Altered SDF-1/CXCR4 axis in patients with primary myelofibrosis and in the Gata1 low mouse model of the disease. Exp Hematol (2008) 1.02

Co-targeting the PI3K/mTOR and JAK2 signalling pathways produces synergistic activity against myeloproliferative neoplasms. J Cell Mol Med (2013) 0.99

Genetic and epigenetic alterations of myeloproliferative disorders. Int J Hematol (2012) 0.97

Enhanced unique pattern of hematopoietic cell mobilization induced by the CXCR4 antagonist 4F-benzoyl-TN14003. Stem Cells (2007) 0.97

Chemokine receptor CXCR4: role in gastrointestinal cancer. Crit Rev Oncol Hematol (2013) 0.95

CXCR4 inhibitors selectively eliminate CXCR4-expressing human acute myeloid leukemia cells in NOG mouse model. Cell Death Dis (2012) 0.94

A perisinusoidal niche for extramedullary haematopoiesis in the spleen. Nature (2015) 0.91

JAK2 mutants (e.g., JAK2V617F) and their importance as drug targets in myeloproliferative neoplasms. JAKSTAT (2013) 0.91

Combination treatment for myeloproliferative neoplasms using JAK and pan-class I PI3K inhibitors. J Cell Mol Med (2013) 0.90

The bone marrow stroma in hematological neoplasms--a guilty bystander. Nat Rev Clin Oncol (2011) 0.89

Identification of hepatic niche harboring human acute lymphoblastic leukemic cells via the SDF-1/CXCR4 axis. PLoS One (2011) 0.88

The role of Janus Kinase 2 V617F mutation in extramedullary hematopoiesis of the spleen in neoplastic myeloid disorders. Mod Pathol (2007) 0.85

JAK2 and MPL protein levels determine TPO-induced megakaryocyte proliferation vs differentiation. Blood (2014) 0.81

Definition and management of ruxolitinib treatment failure in myelofibrosis. Blood Cancer J (2014) 0.80

JAK tyrosine kinases promote hierarchical activation of Rho and Rap modules of integrin activation. J Cell Biol (2013) 0.80

JAK2 tyrosine kinase mediates integrin activation induced by CXCL12 in B-cell chronic lymphocytic leukemia. Oncotarget (2015) 0.79

C-X-C motif chemokine 12 influences the development of extramedullary hematopoiesis in the spleens of myelofibrosis patients. Exp Hematol (2014) 0.79